

Substitute for FORM 1449A/B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number:	10/567,766
Filing Date:	February 10, 2008
First Named Inventor:	Hideki Hasegawa
Group Art Unit:	Unassigned
Confirmation Number:	5580
Examiner Name:	Unassigned
Attorney Docket Number:	43512-103808

U.S. PATENT DOCUMENTS

Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			
	A A	3,906,092		Hilleman et al.	Sep. 16, 1975	
	A B	4,024,222		Ts'o et al.	May 17, 1977	
	A C	4,130,641		Ts'o et al.	Dec. 19, 1978	
	A D	4,795,744		Carter	Jan. 3, 1989	
	A E	4,820,696		Carter	Apr. 11, 1989	
	A F	4,945,082		Carter	July 31, 1990	
	A G	4,950,652		Carter	Aug. 21, 1990	
	A H	4,963,532		Carter	Oct. 16, 1990	
	A I	5,063,209		Carter	Nov. 5, 1991	
	A J	5,091,374		Carter	Feb. 25, 1992	
	A K	5,194,245		Carter	Mar. 16, 1993	
	A L	5,712,257		Carter	Jan. 27, 1996	
	A M	5,906,980		Carter	May 25, 1999	
	A N	6,130,206		Carter	Oct. 10, 2000	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No**
	A O	JP	50-082226		The Johns Hopkins University	Jul. 3, 1975		X*
	A P	JP	62-077334		Hem Res. Inc.	Apr. 9, 1987		X*
	A Q	JP	64-90126		Hem Res. Inc.	Apr. 6, 1989		X*
	A R	JP	2005516294	T	Loeb Health Research Institute at the Ottawa Hospital	Jun. 4, 2002		X*
	A S	JP	2002526425	T	The Regents of the University of California	Aug. 20, 2002		X*
	A T	JP	2002536293	T	Children's Hospital Medical Center	Oct. 29, 2002		X*
	A U	JP	2003510282	T	University of Iowa Research Foundation	Mar. 18, 2003		X*
	A V	WO	99/61056	A2	Loeb Health Research Institute at the Ottawa Hospital et al.	Dec. 2, 1999		
	A W	WO	00/20039	A1	The Regents of the University of California	Apr. 13, 2000		
	A X	WO	00/26380	A1	Children's Hospital Medical Center	May 11, 2000		
	A Y	WO	01/22972	A2	Iowa State University Research Foundation et al.	Apr. 5, 2001		

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AB/

EXAMINER	/Agnieszka Boesen/	DATE CONSIDERED	05/10/2009
----------	--------------------	-----------------	------------

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Substitute for FORM 1449A/B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number:	10/567,766
Filing Date:	February 10, 2006
First Named Inventor:	Hideki Hasegawa
Group Art Unit:	Unassigned
Confirmation Number:	5560
Examiner Name:	Unassigned
Attorney Docket Number:	43512-103808

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	A Z	Avramidis et al., "Adjuvant Regulation of Cytokine Profile and Antibody Isotype of Immune Responses to Mycoplasma Agalactiae in Mice," <i>Veterinary Microbiology</i> , 88: 325-338 (2002).		
	BA	Knopf et al., "Antibody in Tears Following Intranasal Vaccination With Inactivated Virus: II. Enhancement of Tear Antibody Production By the Use of Polyinosinic Polycytidilic Acid (Poly I:C)," <i>Investigative Ophthalmology</i> , 10:10 750-759 (1971)		
	BB	Knopf et al., "Antibody in Tears Following Intranasal Vaccination With Inactivated Virus: III. Role of Tear and Serum Antibody in Experimental Vaccinia Conjunctivitis," <i>Investigative Ophthalmology</i> , 10:10 760-769 (1971)		
	BC	Tamura et al., "Cross-Protection Against Influenza Virus Infection Afforded By Trivalent Inactivated Vaccines Inoculated Intranasally With Cholera Toxin B Subunit," <i>The Journal of Immunology</i> , 149:3 981-988 (1992).		
	BD	Turner et al., "Stimulation of Humoral and Cellular Antibody Formation In Mice By Poly I:C," <i>Proc. Soc. Exp. Biol. & Med.</i> , 133: 334-338 (1970).		
	BE	Wang et al., "Noncoding RNA Danger Motifs Bridge Innate and Adaptive Immunity and Are Potent Adjuvants for Vaccination," <i>The Journal of Clinical Investigation</i> , 110:8 1175-1184 (2002).		

CITD501 CLARCHER 372471v1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AB/

EXAMINER	/Agnieszka Boesen/	DATE CONSIDERED	05/10/2009
----------	--------------------	-----------------	------------

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).